Evidence map›Paper›PMID 41667571›Full record

ArticleScientific reports2026

Chemical synthesis of novel aminopyrimidin-4-yl-1H-pyrazole derivatives as spleen tyrosine kinase (SYK) inhibitors.

K V Rajasheker, M S Pallavi, Pallavi Singh, Victor Stupin, Ekaterina Silina, Kavitharaj Varadaraju, Mohammad Y Alfaifi, Ali A Shati, Serag Eldin I Elbehairi, Chandan Shivamallu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

K V RajashekerSchool of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysore, 570 026, Karnataka, India.
M S PallaviSchool of Computing, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysore, 570 026, Karnataka, India.
Pallavi SinghDepartment of Biotechnology, Graphic Era Deemed to be University, Dehradun, 248 002, Uttarakhand, India. pallavisingh.bt@geu.ac.in.
Victor StupinDepartment of Surgery, Pirogov Russian National Research Medical University, 117997, Moscow, Russia.
Ekaterina SilinaInstitute of Digital Biodesign and Modeling of Living Systems, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991, Moscow, Russia.
Kavitharaj VaradarajuBioscience CLIx, Vivekananda Nagar, Mysore, 570 023, Karnataka, India.
Mohammad Y AlfaifiBiology Department, Faculty of Science, King Khalid University, Abha, 9004, Saudi Arabia.
Ali A ShatiBiology Department, Faculty of Science, King Khalid University, Abha, 9004, Saudi Arabia.
Serag Eldin I ElbehairiBiology Department, Faculty of Science, King Khalid University, Abha, 9004, Saudi Arabia.
Chandan ShivamalluDepartment of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysore, 570 015, Karnataka, India.
ManviAurigene Pharmaceuticals (APSL), Electronic City, Bengaluru, 560 100, Karnataka, India.
P C ArunAurigene Pharmaceuticals (APSL), Electronic City, Bengaluru, 560 100, Karnataka, India.
Shiva Prasad KollurSchool of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysore, 570 026, Karnataka, India. shivachemist@gmail.com.

Funding

King Khalid University RGP.2/361/45
6 · The paper itself

Abstract

Spleen tyrosine kinase (SYK) plays a pivotal role in immunoreceptor signalling pathways implicated in various cancers and autoimmune diseases. Inhibition of SYK has shown therapeutic potential by attenuating immune-mediated damage and suppressing tumour growth. This study reports the synthesis, characterization, and evaluation of a novel series of aminopyrimidin-4-yl-1H-pyrazole derivatives (31, 35, 36, 37, 39, 41, 44, 47 and 49) as selective SYK inhibitors. The chemically synthesized molecules were structurally confirmed using

Indexed as

Protein Kinase InhibitorsPyrazolesSyk KinaseHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingTyrosine Kinase InhibitorsProtein Kinase InhibitorsPyrazolesSyk KinaseSYK protein, humanTyrosine Kinase InhibitorsAminopyrimidin-4-yl-1H-pyrazoleCancer therapeuticsMD simulationSDG3SYK inhibitors

Identifiers

PMID41667571
PMCPMC12966409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.